文献速递心脑血管急症

PCI术后3个月DAPT后P2Y12抑制剂单药治疗对比双联抗血小板治疗对心血管事件的影响:SMART-CHOICE随机临床试验

Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial.
PubMed 文献 · JAMA · 2019-01-01
一句话结论PCI术后3个月DAPT后改用P2Y12抑制剂单药,12个月主要不良心脑血管事件不劣于12个月DAPT,出血更少。

SMART-CHOICE试验在韩国33家医院纳入2993例接受药物洗脱支架PCI的患者,随机分为3个月DAPT后P2Y12抑制剂单药组(n=1495)或12个月DAPT组(n=1498)。12个月时主要不良心脑血管事件(全因死亡、心肌梗死或卒中复合终点)单药组2.9% vs DAPT组2.5%,差异0.4%(单侧95%CI -∞%至1.3%),非劣效性P=0.007。出血(BARC 2-5型)单药组2.0% vs DAPT组3.4%(HR 0.58,95%CI 0.36-0.92,P=0.02)。结论认为PCI术后3个月DAPT后P2Y12抑制剂单药不劣于延长DAPT,但因研究人群和依从性限制,需在其他人群进一步研究。

要点

  • PCI术后3个月DAPT后P2Y12抑制剂单药组12个月主要不良心脑血管事件2.9% vs 12个月DAPT组2.5%,差异0.4%(单侧95%CI -∞%至1.3%),非劣效性P=0.007。
  • 出血(BARC 2-5型)单药组2.0% vs DAPT组3.4%,HR 0.58(95%CI 0.36-0.92),P=0.02,单药组显著降低。
  • 全因死亡(1.4% vs 1.2%;HR 1.18,95%CI 0.63-2.21)、心肌梗死(0.8% vs 1.2%;HR 0.66,95%CI 0.31-1.40)、卒中(0.8% vs 0.3%;HR 2.23,95%CI 0.78-6.43)两组无显著差异。
  • 研究为非劣效性设计,非劣效界值1.8%;方案依从性单药组79.3% vs DAPT组95.2%。
  • 作者认为因研究人群和依从性限制,需在其他人群进一步研究。

适用人群与场景

  • 接受经皮冠状动脉介入治疗并植入药物洗脱支架的患者(SMART-CHOICE试验纳入人群)。
  • 研究在韩国33家医院进行,共2993例患者,平均年龄64岁,女性795例(26.6%)。

诊断标准与关键阈值

  • 非劣效性界值为1.8%。
  • 主要终点为术后12个月主要不良心脑血管事件,即全因死亡、心肌梗死或卒中的复合终点。
  • 出血终点定义为Bleeding Academic Research Consortium 2至5型。

处置流程与药物剂量

  • 随机分为两组:3个月DAPT(阿司匹林联合一种P2Y12抑制剂)后P2Y12抑制剂单药治疗(n=1495),或DAPT持续12个月(n=1498)。
  • 研究方案未明确P2Y12抑制剂具体药名、剂量、给药途径及频次。

研究设计与关键结果

  • SMART-CHOICE为开放标签、非劣效性随机研究,在韩国33家医院纳入2993例接受PCI并植入药物洗脱支架的患者;入组始于2014年3月18日,随访于2018年7月19日完成。
  • 12个月时主要不良心脑血管事件:P2Y12抑制剂单药组42例(2.9%)vs DAPT组36例(2.5%),差异0.4%(单侧95%CI -∞%至1.3%),非劣效性P=0.007。
  • 全因死亡:单药组21例(1.4%)vs DAPT组18例(1.2%),HR 1.18(95%CI 0.63-2.21),P=0.61。
  • 心肌梗死:单药组11例(0.8%)vs DAPT组17例(1.2%),HR 0.66(95%CI 0.31-1.40),P=0.28。
  • 卒中:单药组11例(0.8%)vs DAPT组5例(0.3%),HR 2.23(95%CI 0.78-6.43),P=0.14。
  • 出血(BARC 2-5型):单药组2.0% vs DAPT组3.4%,HR 0.58(95%CI 0.36-0.92),P=0.02。
  • 2912例(97.3%)完成试验;方案依从性:P2Y12抑制剂单药组79.3%,DAPT组95.2%。

证据类型、等级与局限

  • 证据类型:开放标签、非劣效性随机临床试验(SMART-CHOICE)。
  • 作者指出因研究人群和依从性限制,需在其他人群进一步研究。

对床旁实践的改变

  • 对于接受PCI并植入药物洗脱支架的患者,作者认为3个月DAPT后P2Y12抑制剂单药治疗相比12个月DAPT,主要不良心脑血管事件不劣于后者,且出血更少。
  • 作者指出因研究人群和依从性限制,需在其他人群进一步研究。

指南或共识出处

  • SMART-CHOICE随机临床试验(ClinicalTrials.gov标识符:NCT02079194)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Data on P2Y12 inhibitor monotherapy after short-duration dual antiplatelet therapy (DAPT) in patients undergoing percutaneous coronary intervention are limited.

OBJECTIVE: To determine whether P2Y12 inhibitor monotherapy after 3 months of DAPT is noninferior to 12 months of DAPT in patients undergoing PCI.

DESIGN, SETTING, AND PARTICIPANTS: The SMART-CHOICE trial was an open-label, noninferiority, randomized study that was conducted in 33 hospitals in Korea and included 2993 patients undergoing PCI with drug-eluting stents. Enrollment began March 18, 2014, and follow-up was completed July 19, 2018.

INTERVENTIONS: Patients were randomly assigned to receive aspirin plus a P2Y12 inhibitor for 3 months and thereafter P2Y12 inhibitor alone (n = 1495) or DAPT for 12 months (n = 1498).

MAIN OUTCOMES AND MEASURES: The primary end point was major adverse cardiac and cerebrovascular events (a composite of all-cause death, myocardial infarction, or stroke) at 12 months after the index procedure. Secondary end points included the components of the primary end point and bleeding defined as Bleeding Academic Research Consortium type 2 to 5. The noninferiority margin was 1.8%.

RESULTS: Among 2993 patients who were randomized (mean age, 64 years; 795 women [26.6%]), 2912 (97.3%) completed the trial. Adherence to the study protocol was 79.3% of the P2Y12 inhibitor monotherapy group and 95.2% of the DAPT group. At 12 months, major adverse cardiac and cerebrovascular events occurred in 42 patients in the P2Y12 inhibitor monotherapy group and in 36 patients in the DAPT group (2.9% vs 2.5%; difference, 0.4% [1-sided 95% CI, -∞% to 1.3%]; P = .007 for noninferiority). There were no significant differences in all-cause death (21 [1.4%] vs 18 [1.2%]; hazard ratio [HR], 1.18; 95% CI, 0.63-2.21; P = .61), myocardial infarction (11 [0.8%] vs 17 [1.2%]; HR, 0.66; 95% CI, 0.31-1.40; P = .28), or stroke (11 [0.8%] vs 5 [0.3%]; HR, 2.23; 95% CI, 0.78-6.43; P = .14) between the 2 groups. The rate of bleeding was significantly lower in the P2Y12 inhibitor monotherapy group than in the DAPT group (2.0% vs 3.4%; HR, 0.58; 95% CI, 0.36-0.92; P = .02).

CONCLUSIONS AND RELEVANCE: Among patients undergoing percutaneous coronary intervention, P2Y12 inhibitor monotherapy after 3 months of DAPT compared with prolonged DAPT resulted in noninferior rates of major adverse cardiac and cerebrovascular events. Because of limitations in the study population and adherence, further research is needed in other populations.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02079194.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Hahn JY, Song YB, Oh JH, et al. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial. JAMA. 2019. PMID: 31237645. doi:10.1001/jama.2019.8146

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。